

Statement of Principles

concerning

MALIGNANT NEOPLASM OF THE BILE DUCT
 (Balance of Probabilities)

(No. 54 of 2024)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the *Veterans' Entitlements Act 1986*.

Dated 21 June 2024.

|  |
| --- |
| Professor Terence Campbell AMChairpersonby and on behalf of The Repatriation Medical Authority |
|  |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Repeal 3

5 Application 3

6 Definitions 3

7 Kind of injury, disease or death to which this Statement of Principles relates 3

8 Basis for determining the factors 4

9 Factors that must exist 4

10 Relationship to service 5

11 Factors referring to an injury or disease covered by another Statement of Principles 6

Schedule 1 - Dictionary 7

1 Definitions 7

1. Name

This is the Statement of Principles concerning *malignant neoplasm of the bile duct* *(Balance of Probabilities)* (No. 54 of 2024).

1. Commencement

 This instrument commences on 23 July 2024.

1. Authority

This instrument is made under subsection 196B(3) of the *Veterans' Entitlements Act 1986*.

1. Repeal

The Statement of Principles concerning malignant neoplasm of the bile duct No. 70 of 2015 (Federal Register of Legislation No. F2015L00655) made under subsections 196B(3) and (8) of the VEA is repealed.

1. Application

This instrument applies to a claim to which section 120B of the VEA or section 339 of the *Military Rehabilitation and Compensation Act 2004* applies.

1. Definitions

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

1. Kind of injury, disease or death to which this Statement of Principles relates
	1. This Statement of Principles is about malignant neoplasm of the bile duct and death from malignant neoplasm of the bile duct.

Meaning of **malignant neoplasm of the bile duct**

* 1. For the purposes of this Statement of Principles, malignant neoplasm of the bile duct:
		1. means a primary malignant neoplasm arising from the epithelial cells of the intrahepatic or extrahepatic bile ducts (including the ampulla of Vater and the cystic duct); and
		2. includes:
			1. cholangiocarcinoma;
			2. Klatskin tumour (hilar cholangiocarcinoma);
			3. squamous cell carcinoma of the bile duct;
			4. adenosquamous carcinoma of the bile duct;
			5. undifferentiated carcinoma of the bile duct;
			6. lymphoepithelioma-like cholangiocarcinoma; and
			7. adenocarcinoma of ampulla of Vater; and
		3. excludes:
			1. soft tissue sarcoma;
			2. malignant neoplasm of the gallbladder;
			3. neuroendocrine carcinoma of the gallbladder;
			4. non-Hodgkin lymphoma; and
			5. Hodgkin lymphoma.
	2. While malignant neoplasm of the bile duct attracts ICD‑10‑AM code C22.1, C24.0 and C24.1, in applying this Statement of Principles the meaning of malignant neoplasm of the bile duct is that given in subsection (2).
	3. For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in *The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification* (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.

Death from **malignant neoplasm of the bile duct**

* 1. For the purposes of this Statement of Principles, malignant neoplasm of the bile duct,in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the bile duct.

Note: ***terminal event*** is defined in the Schedule 1 – Dictionary.

1. Basis for determining the factors

On the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that malignant neoplasm of the bile duct and death from malignant neoplasm of the bile duct can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: ***MRCA***, ***relevant service*** and ***VEA*** are defined in the Schedule 1 – Dictionary.

1. Factors that must exist

At least one of the following factors must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the bile duct or death from malignant neoplasm of the bile duct is connected with the circumstances of a person's relevant service:

* 1. having an infestation of the hepatobiliary tract with the liver flukes *Clonorchis sinensis, Opisthorchis viverrini* before clinical onset;
	2. having primary sclerosing cholangitis before clinical onset;
	3. having inflammatory bowel disease before clinical onset;
	4. having cholelithiasis, choledocholithiasis or hepatolithiasis before the clinical onset of malignant neoplasm of the bile duct;

Note: Cholelithiasis relates to the formation of stones in the gallbladder, choledocholithiasis relates to stones in the bile ducts, and hepatolithiasis relates to stones in the bile ducts inside the liver.

* 1. having had an injection of Thorotrast (thorium dioxide) before clinical onset;
	2. having cirrhosis of the liver before clinical onset;
	3. having chronic infection with the hepatitis B virus at the time of clinical onset;

Note: ***chronic infection with hepatitis B virus*** is defined in the Schedule 1 – Dictionary.

* 1. having chronic infection with the hepatitis C virus at the time of clinical onset;

Note: ***chronic infection with hepatitis C virus*** is defined in the Schedule 1 – Dictionary.

* 1. having diabetes mellitus for at least 5 years before clinical onset;
	2. being obese for at least 10 years within the 20 years before clinical onset;

Note: ***being obese*** is defined in the Schedule 1 – Dictionary.

* 1. undergoing solid organ transplantation excluding corneal transplant, at least 5 years before clinical onset;
	2. having non-alcoholic fatty liver disease for at least 5 years within the 20 years before clinical onset;
	3. consuming at least 640 kilograms of alcohol at least 5 years before clinical onset;
	4. inhaling, ingesting or having cutaneous contact with 1,2-dichoropropane for at least 1,000 ppm-years at least 5 years before the clinical onset of malignant neoplasm of the bile duct;

Note: ***ppm-years*** is defined in the Schedule 1 – Dictionary.

* 1. inability to obtain appropriate clinical management for malignant neoplasm of the bile duct before clinical worsening.
1. Relationship to service
	1. The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
	2. The factor set out in subsection 9(15) applies only to material contribution to, or aggravation of, malignant neoplasm of the bile duct where the person's malignant neoplasm of the bile duct was suffered or contracted before or during (but did not arise out of) the person's relevant service.
2. Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

* 1. if a factor referred to in section 9 applies in relation to a person; and
	2. that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

Schedule 1 - Dictionary

Note: See Section 6

1. Definitions
	1. In this instrument:
		1. ***being obese*** means:
			1. having a Body Mass Index (BMI) of 30 or greater; or
			2. for males, having a waist circumference exceeding 102 centimetres; or
			3. for females, having a waist circumference exceeding 88 centimetres.

Note: ***BMI*** is defined in the Schedule 1 - Dictionary.

* + 1. ***BMI*** means W/H2 where:
			1. W is the person's weight in kilograms; and
			2. H is the person's height in metres.
		2. ***chronic infection with the hepatitis B virus*** means:
		3. infection with the hepatitis B virus resulting in a chronic infection of at least six months duration and which must be confirmed by laboratory testing for hepatitis B serological or nucleic acid markers, or both.
		4. ***chronic infection with the hepatitis C virus*** means:
		5. infection with the hepatitis C virus resulting in a chronic infection of at least six months duration and which must be confirmed by laboratory testing for hepatitis C serological or nucleic acid markers, or both.
		6. ***malignant neoplasm of the bile duct***—see subsection 7(2).
		7. ***MRCA*** means the *Military Rehabilitation and Compensation Act 2004*.
		8. ***ppm-years*** means parts per million multiplied by years of exposure.
		9. ***relevant service*** means:
			1. eligible war service (other than operational service) under the VEA;
			2. defence service (other than hazardous service and British nuclear test defence service) under the VEA; or
			3. peacetime service under the MRCA.

Note: ***MRCA*** and ***VEA*** are also defined in the Schedule 1 - Dictionary.

* + 1. ***terminal event*** means the proximate or ultimate cause of death and includes the following:
			1. pneumonia;
			2. respiratory failure;
			3. cardiac arrest;
			4. circulatory failure; or
			5. cessation of brain function.
		2. ***VEA*** means the *Veterans' Entitlements Act 1986*